Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VEGFc and VEGFR3 expression in human thyroid pathologies.

S Shushanov1, M Bronstein, J Adélaïde

  • 1Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russia.

International Journal of Cancer
|March 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.

Nature structural & molecular biology·2020
Same author

SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.

Nature structural & molecular biology·2020
Same author

Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020
Same author

Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.

Blood cancer journal·2017

Vascular Endothelial Growth Factor C (VEGFc) and its receptor VEGFR3 are expressed in various thyroid conditions. Their co-expression in thyroid tumors suggests a role in lymphatic biology and disease progression.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGFRs) regulate angiogenesis in vertebrates.
  • In adults, VEGFc and VEGFR3 are key players in lymphatic system biology.
  • VEGFR3, also known as FLT4, is a critical receptor in this pathway.

Purpose of the Study:

  • To investigate the expression of VEGFR3 and VEGFc in diverse human thyroid pathologies.
  • To determine the presence of VEGFR3 (short and long forms) and VEGFc mRNA and proteins in thyroid tissues.
  • To explore the co-expression patterns of VEGFR3 and VEGFc in thyroid tumors.

Main Methods:

  • Reverse transcription polymerase chain reaction (RT-PCR) was used to analyze gene expression.
  • Immunohistochemistry with specific antibodies was employed to detect protein expression.

Related Experiment Videos

  • Analysis covered 38 human thyroid tissue samples, including various pathologies.

    • Main Results:

    • VEGFR3 mRNA was detected in all examined adenomas, nodular goiters, and focal goitrogenic alterations.
    • VEGFR3 mRNA was also found in all thyroid tissues from patients with autoimmune diseases and in some adenocarcinomas.
    • VEGFc mRNA was detected in most samples, and co-expression of VEGFR3 and VEGFc proteins was observed in the majority of thyroid tumors.

    Conclusions:

    • VEGFR3 and VEGFc are widely expressed in various benign and malignant thyroid conditions.
    • The co-expression of VEGFR3 and VEGFc suggests their involvement in the pathogenesis of thyroid diseases, potentially through lymphatic mechanisms.
    • Further research is warranted to elucidate the specific roles of VEGFc/VEGFR3 signaling in thyroid cancer and other thyroid disorders.